Medley (4480.T) traded up 0.57 % during a 24 hours period ending at 09:54 PM Central Europe on Tuesday 27th. One Medley stock can currently be bought for about JPY 2,394 on popular exchanges. Current supply of Medley stocks is 30.2 mn. Medley has a current market capitalization of JPY 74.8 bn and approximately JPY 381.9 mn worth of Medley was traded on exchanges in the last 24 hours. Since last month end, Medley has traded 4.52 % up. Simple moving average of last 200 days is at JPY 2,221.9. The highest price of past 52 weeks was recorded at JPY 3,040 on 08/17/2026. 52 weeks low was at JPY 1,715 on 03/23/2026.

Here is how related stocks have performed in the past 24 hours:

  • Qol (3034.T) traded down -0.21 % and now trades at JPY 2,280. Current market capitalisation for Qol is JPY 88.8 bn. Qol has a current price to earnings ratio of 10.36.

  • Prestige (4290.T) traded up 0.42 % and now trades at JPY 704. Current market capitalisation for Prestige is JPY 88.6 bn. Current price/earnings ratio for Prestige is 14.82.

  • Miraini (546A.T) traded up 0.62 % and now trades at JPY 2,472. Miraini has a market capitalisation of JPY 88.6 bn.

  • Tokai /Gifu (9729.T) traded up 1.07 % and now trades at JPY 2,940. Tokai /Gifu has a market capitalisation of JPY 89.8 bn. Tokai /Gifu has a current price to earnings ratio of 15.28.

  • Zeria Pharmaceutical (4559.T) traded up 0.3 % and now trades at JPY 1,985. Current market capitalisation for Zeria Pharmaceutical is JPY 89.5 bn. Zeria Pharmaceutical has a current price to earnings ratio of 10.89. Zeria Pharmaceutical Co., Ltd., through its subsidiary Tillotts Pharma AG, has announced the planned acquisition of Haupt Pharma Wülfing GmbH in Gronau, Germany. The transaction aims to strengthen Zeria’s manufacturing base, enhance flexibility for future growth, and support long‑term supply security for its gastrointestinal drug portfolio. The agreement, signed on 23 October 2026, will integrate approximately 280 employees and expand production capacity for key products such as Asacol. While the purchase price remains undisclosed, Zeria intends to invest significantly in modernising the Gronau site, improving quality and efficiency, and preparing the facility for continued expansion. The move aligns with Zeria’s strategy to maintain a robust, specialised production network across multiple countries, ensuring reliable delivery of high‑quality therapeutic products to patients worldwide.

About Medley

The Tokyo Stock Exchange is a leading financial institution located in Japan, which provides a platform for companies like Medley Inc. to list their securities and gain access to the capital markets for fundraising purposes.